The anti-HBc test (reagent, 72448M100) at 1 mIU/mL was considered to be positive

The anti-HBc test (reagent, 72448M100) at 1 mIU/mL was considered to be positive. response was correlated with the pre-booster titer level, and 1 . 0 mIU/mL ensuring a robust positive response, whereas titers below this value may indicate the need for a course of booster vaccination. KEYWORDS: anti-HBs, booster vaccination, HBV, immunogenicity effect, 5-year follow-up == Introduction == Hepatitis B virus (HBV) infection is one of the leading causes of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, and has a worldwide distribution with significant morbidity and mortality. 1-3Vaccination is the most efficient and safest method of conferring long-term protection against the virus. 4In 1992, the World Health Organization (WHO) endorsed the recommendation for the integration of HBV vaccination into national immunization, 5with a target for worldwide implementation by 1997. In 2008, universal childhood HBV vaccination programs were administered in 177 countries, leading to substantial reduction in the global burden and transmission of HBV-associated complications. 6 A national seroepidemiological survey in 2006 revealed a high HBV infection rate in China, with an HBsAg carrier rate of 7. 2% in 159 y old individuals. Since 1992, Ibuprofen (Advil) universal infant vaccination planning began in China and 2005, the government required that all infant vaccinations be administered free of cost. After decades of hepatitis B mass vaccination, a national serosurvey in 2006 showed the prevalence of HBsAg in Chinese population aged 159 y had decreased to 7. 2%, from 9. 8% in 1992, and the number of HBV-infected children has declined by 80 million. 7, 8 The long-term protection induced by 3 doses of hepatitis B vaccine is well-established. Mouse monoclonal to CD64.CT101 reacts with high affinity receptor for IgG (FcyRI), a 75 kDa type 1 trasmembrane glycoprotein. CD64 is expressed on monocytes and macrophages but not on lymphocytes or resting granulocytes. CD64 play a role in phagocytosis, and dependent cellular cytotoxicity ( ADCC). It also participates in cytokine and superoxide release Previous studies have demonstrated that the majority of individuals elicit a strong anamnestic response upon exposure to HBV even 1015 years after primary vaccination in infancy. 9-11However, a number of studies have indicated that the antibody titers decline with increasing age following immunization, leading a higher risk of infection. 12, 13In addition, a small number of vaccination failures occur. 14, 15Approximately 1020% of neonatal HBV vaccines develop an anergy or a poor response, and 5% acquire HBV infections despite vaccination. 16-19HBV vaccine failure may be attributed to an immature immune system. Consequently, the necessity of booster vaccination raises concern. While our earlier study20has observed that, the one year effect of a 3-dose revaccination in anti-HBs negative children was closely related to their pre-booster level of anti-HBs. The follow-up periods of most previous studies were short. Hence, a longer follow-up is essential to assess the HBV revaccination efficacy. In the present study, which is a follow-up to our previous study, 20we examined protective Ibuprofen (Advil) immunity to HBV in 225 children whose anti-HBs levels were <10. 0 mIU/mL more than 10 years after primary vaccination; we evaluated the efficacy of the 3-dose booster over a 5-year follow-up period. == Results == In all, total of 2022 children were investigated and 795 children were selected and enrolled. One month after Ibuprofen (Advil) the first dose, 9 subjects refused to blood sample collection. One month after the third dose, 21 subjects dropped out of the study. One year after vaccination, 206 subjects were unavailable to follow-up. Four years later, 225 subjects were remaining while the other 299 were lost to follow-up (Fig. 1). The 225 participants included 123 males and 102 females, with an average age of 9. 28 2 Ibuprofen (Advil) . 95 years. 41, 69, and 115 subjects were randomized into 3 groups, respectively. No statistically significant differences were observed in age or gender between the groups (Table 1). == Figure 1 . == Study flow chart. Anti-HBs level prior to immune booster: Group I < 0. 1 mIU/mL; Group II 0. 1 to < 1 . 0 mIU/mL; Group III 1 . 0 to < 10. 0 mIU/mL. *1022 subjects (5-15 y old) in this study included 841 children (11-15 y old) in our previous study. 20 == Table 1 . == Age and sex distribution Ibuprofen (Advil) of study subjects. anti-HBs level.